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Abstract 
Macrophage migration inhibitory factor (MIF) has been found to be involved in host resistance 
to several parasitic infections. To determine the mechanisms of the MIF-dependent responses 
to Trypanosoma cruzi, we investigated host resistance in MIF-/- mice (on the BALB/c back-
ground) during an intraperitoneal infection. We focused on the potential involvement of MIF 
in dendritic cell (DC) maturation and cytokine production. Following a challenge with 5 x 10
3 
T. cruzi parasites, wild type (WT) mice developed a strong IL-12 response and adequate 
maturation of the draining mesenteric lymph node DCs and were resistant to infection. In 
contrast, similarly infected MIF
-/- mice mounted a weak IL-12 response, displayed immature 
DCs in the early phases of infection and rapidly succumbed to T. cruzi infection. The lack of 
maturation and IL-12 production by the DCs in response to total T. cruzi antigen (TcAg) was 
confirmed by in vitro studies. These effects were reversed following treatment with recom-
binant MIF. Interestingly, TcAg-stimulated bone marrow-derived DCs from both WT and 
MIF
-/- mice had increased ERK1/2 MAPK phosphorylation. In contrast, p38 phosphorylation 
was only upregulated in WT DCs. Reconstitution of MIF to MIF
-/- DCs upregulated p38 
phosphorylation. The MIF-p38 pathway affected MHC-II and CD86 expression as well as IL-12 
production. These findings demonstrate that the MIF-induced early DC maturation and IL-12 
production mediates resistance to T. cruzi infection, probably by activating the p38 pathway. 
Key words: Macrophage migration inhibitory factor, Trypanosoma cruzi, macrophages, dendritic 
cells, p38 MAPK, ERK1/2 MAPK. 
Introduction 
Chagas  disease,  which  is  caused  by  the  proto-
zoan parasite T. cruzi, is the most important parasitic 
infection in Latin America [1]. An estimated 10 million 
people  carry  the  infection,  while  another  90  million 
live at risk [2, 3]. This parasitic disease is transmitted 
by the feces of bloodsucking insect vectors (Triatoma) 
[4]. T. cruzi has a fundamental role in inducing im-
munopathology and tissue damage in organs such as 
the  heart,  esophagus  and  colon  by  sequentially  in-
ducing  inflammatory responses, cellular lesions and 
fibrosis [4-7]. Host resistance to experimental acute T. 
cruzi  infection  is  dependent  on  both  the  innate  and 
acquired  immune  responses  mediated  by  macro-
phages (MOs), natural killer (NK) cells, CD4+ T cells, 
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CD8+ T cells, and B cells  [5, 8]. The innate immune 
response to T. cruzi involves the production of cyto-
kines that have the capacity to regulate NK cell and 
MO activity, such as interferon (IFN)-, IFN-, inter-
leukin (IL)-12 and tumor necrosis factor (TNF)- [5, 
9-13], since genetically engineered mice lacking any of 
these cytokines fail to control parasitemia and rapidly 
succumb to T. cruzi infection  [14, 15]. However, the 
mechanisms  involved  in  the  innate  immune  protec-
tion  against  T  cruzi  are  not  completely  understood 
[13]. Part of the protective role of the innate cytokines 
may  therefore  be  through  the  regulation  of  IL-12, 
which  enhances  TNF-  and  IFN-  production  from 
NK cells [16]. Both TNF- and IFN- are required for 
the induction of the nitric oxide-dependent microbi-
cidal  activity  of  MOs  [17].  In  contrast,  the  an-
ti-inflammatory cytokines IL-4, IL-10 and transform-
ing growth factor (TGF)-β mediate susceptibility to T. 
cruzi  but  are  also  required  for  preventing  immune 
hyperactivity and organ immunopathology [7, 18, 19].  
MIF is a pleiotropic cytokine that is produced by 
multiple different cell types, such as T cells, activated 
MOs, and dendritic cells (DCs) [20-23]. Upon release, 
MIF modulates the expression of several proinflam-
matory molecules, including cytokines (TNF-, IFN-, 
IL-1,  IL-2,  IL-6  and  IL-8),  nitric  oxide,  and  COX2 
[24-26].  Moreover,  MIF  is  required  for  resistance  to 
several  pathogens  that  express  TLR  ligands.  It  is 
known that one of the main effects of MIF on the im-
mune system is the upregulation of TLR4 expression 
[27], which contributes to the resistance of MIF-/- mice 
to LPS-induced sepsis [28].  
It  is  known  that  MIF  is  critical  for  controlling 
acute  T. cruzi infection  [29],  but  the  specific  mecha-
nism of MIF in the resistance to T. cruzi infection is not 
known. 
MIF has the potential to modulate numerous in-
tracellular signaling pathways, including several that 
are known to be involved in the transcription of in-
flammatory cytokines, such as IL-10, IL-13 and TGF-, 
in  MIF-induced  macrophage  activation  [30].  For  ex-
ample,  MIF  deficiency  impairs  mitogen-activated 
protein kinase (MAPK) signaling induced by the pro-
inflammatory  cytokines  IL-1  and  TNF  or  by 
Ag-specific T cell activation [31-34], and MIF also ac-
tivates the PI3K–Akt pathway [35, 36]. Whether MIF 
affects  DC  effector  functions  via  its  effects  on  these 
pathways has not yet been examined. 
The aim of this study was to determine the effect 
of  MIF-deficiency  in  DCs  on  protective  immunity 
against T. cruzi infection. We examined the maturation 
of mesenteric lymph node-derived DCs from WT and 
MIF-/-  mice  after  infection  with  T.  cruzi  in  vivo  or 
pulsing with TcAg in vitro.  Our results indicate that 
the  interaction  of  DCs  with  MIF  during  T. 
cruzi-induced maturation is required for the upregu-
lation  of  MHC  class  II,  costimulatory  molecule  ex-
pression  and  cytokine  secretion  of  mature  DCs. 
Moreover, we demonstrate a synergism between TcAg 
and MIF that favors DC maturation through p38 acti-
vation.  
Materials and Methods 
Mice.  Eight-to-10-week-old  male  BALB/c  mice 
were purchased from Harlan (México City, Mexico). 
MIF-/- mice were developed as described previously 
[37] and were backcrossed for more than ten genera-
tions to a BALB/c genetic background. The mice were 
maintained  in  a  pathogen-free  environment  at  our 
animal  facility  in  accordance  with  institutional  and 
national guidelines. 
Parasite and peritoneal infections. The Mexican 
T.  cruzi  I  Queretaro  (Qro)  (TBAR/MX/0000/ 
Queretaro) strain was donated by Dr. Bertha Espinoza 
from  I.I.B,  UNAM.  Mexico.  Briefly,  the T. cruzi  Qro 
strain  was  isolated  from  the  Triatoma  barberi  vector 
from the Queretaro State in central Mexico [38]. The 
strain was maintained by sequential murine passages. 
Blood trypomastigotes were obtained from previously 
infected  BALB/c  mice,  counted,  and  adjusted  with 
sterile phosphate-buffered saline (PBS) to contain 5 x 
103 parasites  in  each  100  l  aliquot,  and  100  l  was 
injected  intraperitoneally  (i.p.)  into  WT  and  MIF-/- 
male mice. Parasitemia was determined every seven 
days using a hemocytometer and blood diluted 1:50 in 
PBS with heparin. 
Preparation  of  T.  cruzi  total  lysates.  Trypo-
mastigotes  of  T. cruzi  that  had  been  maintained  by 
sequential culture in liver infusion tryptose medium 
were isolated, washed three times in PBS, and centri-
fuged  at  1x104  rpm  for  15  min.  Protease  inhibitors 
were added (0.1-2 g/ml apotinin, 0.5-2 mM EDTA, 
1-5  mM  phenylmethyl  fluoride,  1  g/ml  pepstatin, 
and 50 g/ml TLCK (a-p-tosyl-L-Lysine chloromethyl 
ketone; all from Sigma-Aldrich, St. Louis, MO, USA), 
and  the  parasites  were  washed  twice  in  sterile, 
ice-cold PBS by centrifugation at 200 g for 10 min at 
4°C. The pellets were then frozen in liquid nitrogen 
and thawed at 37°C, and  this process  was repeated 
seven times. Parasite destruction was confirmed using 
a microscope. The parasite lysate was used as the total 
T. cruzi antigen (TcAg). The protein concentration was 
determined by the Lowry method [39], and the lysate 
was stored at -70C until use.  
Cell preparations and culture conditions. Mes-
enteric cells and spleen cells were obtained from WT 
and MIF-/- mice under sterile conditions three, seven, 
ten and fifteen days after an i.p. T. cruzi infection. In Int. J. Biol. Sci. 2011, 7 
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brief, spleen or mesenteric lymph node tissues were 
minced and filtered to obtain cells, which were then 
washed and resuspended in Dulbecco’s modified Ea-
gle medium (DMEM; Invitrogen, Carlsbad, CA) sup-
plemented  with  10%  fetal  calf  serum  (FCS),  2  mM 
L-glutamine,  0.25  U/ml  penicillin  and  100  g/ml 
streptomycin  (all  from  GIBCO,  BRL,  Grand  Island, 
NY,  USA).  The  cells  from  both  tissues  were  resus-
pended at a concentration of 5 x 106 cells/ml and were 
analyzed by flow cytometry.  
Bone marrow-derived murine DCs were differ-
entiated from the bone marrow of uninfected WT and 
MIF-/- mice according to a version of a protocol pre-
viously  described  [40].  Briefly,  bone  marrow  cells 
were flushed from the femurs and tibias of mice with 
DMEM supplemented 10% fetal calf serum (FCS), 2 
mM L-glutamine, 0.25 U/ml penicillin and 100 g/ml 
streptomycin (all from GIBCO). Red blood cells were 
lysed  with  0.83%  ammonium  chloride  (Sig-
ma-Aldrich). After 72 h of incubation with 20 ng/ml 
recombinant  murine  granulocyte-macrophage  colo-
ny-stimulating  factor  (rGM-CSF;  Peprotech-Mexico, 
Mexico)-containing  complete  medium,  non-adherent 
cells were discarded, and the remaining cells were fed 
with rGM-CSF-containing complete medium. On day 
6  of  the  culture,  the  cells  were  fed  with 
rGM-CSF-containing medium, and the non-adherent 
cells were used for experiments on day 6, at which 
point they stained positive (70-80%) for CD11c by flow 
cytometry.  The  cell  suspensions  were  transferred  to 
24-well culture plates (Costar, Cambridge, MA, USA) 
at  5  x  105  cells/well  and  were  stimulated  with  50 
g/ml  TcAg  or  with  1  g/ml  LPS  (Sigma-Aldrich). 
For  the  DCs  from  MIF-/-  mice,  recombinant  murine 
MIF  (rMIF  from  R&D  Systems,  Minneapolis,  MN, 
USA) was added (20 ng/ml) alone or together with 
TcAg or LPS. The plates were then incubated at 37C 
with 5% CO2 for 24 h. In some experiments, the DCs 
were incubated for two hours with a specific p38 in-
hibitor SB203580 at 10 µM (Invivogen, San Diego, CA, 
USA)  before  rMIF,  TcAg or  LPS  treatment,  and  the 
inhibitor control samples were treated with a corre-
sponding  volume  of  DMSO.  The  supernatants  were 
collected, centrifuged, aliquoted and frozen at -20C 
until use.  
Cytokine measurements. The supernatants from 
the  cell  culture  experiments  described  above  were 
analyzed by ELISA to measure the production of MIF, 
IL-12,  IFN-IL-1  and  TNF-  using  kits  as  recom-
mended  by  the  manufacturer  (Peprotech  and  R&D 
Systems).  The  optical  density  (OD)  was  measured 
after  5  minutes  using  an  ELISA  microplate  reader 
(SpectraMax 250, Molecular Devices, USA) at 405 nm. 
Flow cytometry. DCs were collected and stained 
for flow cytometric analysis. The DCs were washed in 
flow  wash  (Dulbecco´s  PBS  containing  1%  FCS  and 
0.05% sodium azide) followed by incubation with al-
lophycocyanin-conjugated anti-CD11c and fluorescein 
isothiocyanate  or  phycoerythrin  (PE)-labeled  an-
ti-MHC-II, CD80, CD86, and OX40L Abs (all antibod-
ies from BioLegend, San Diego, CA, USA) at 4°C for 30 
min. After incubation, the cells were washed several 
times in buffer and were fixed in 1% paraformalde-
hyde (Sigma-Aldrich) and stored at 4°C in darkness 
before analysis using a FACS Calibur and Cell Quest 
software  (Becton  Dickinson,  Franklin  Lakes,  NY, 
USA).   
Detection of phosphorylation by flow cytome-
try. Bone marrow DCs that were obtained after 6 days 
of culture were washed and seeded without GM-CSF 
for 24 h to eliminate any remaining phosphorylation. 
Then 2 x 105 DCs were stimulated for 30 minutes with 
the  different  treatments.  After  stimulation,  the  DCs 
were fixed with 2% paraformaldehyde for 10 minutes 
at room temperature (RT). The cells were washed with 
staining  buffer  and  permeabilized  with  ice-cold 
methanol  for  10  minutes  at  4ºC  (all  from  Sig-
ma-Aldrich).  The  cells  were  washed  with  staining 
buffer two times and were incubated 15 minutes with 
anti-CD16/32. A primary rabbit anti-mouse antibody 
against ERK or p38 (both from Biovision, San Diego, 
CA,  USA)  was  added  at  1:1000,  and  the  cells  were 
incubated for 20 minutes in the dark at RT. Finally, the 
cells were labeled with a secondary antibody, donkey 
anti-rabbit  DyLight  488  (BioLegend),  at  0.25  µg/106 
cells for 20 minutes at RT in the dark, and flow cy-
tometry was performed.                                                                                                                      
Statistical analysis. The data are expressed as the 
means +/- the standar error (SE). The statistical sig-
nificance  of  the  differences  in  the  mean  values  was 
determined using Student’s t test. The survival data 
are  presented  as  Kaplan-Meier  survival  curves  and 
were  analyzed  using  the  Log-rank  test.  P<0.05  was 
considered significant. 
Results 
Disease progression and parasitism in WT and 
MIF-/- mice over the course of T. cruzi infection 
It  has  been  shown  that  the  genetic  ablation  of 
MIF rendered mice highly susceptible to intraperito-
neal infection with T. cruzi [29]. WT and MIF-/- mice 
were infected by i.p. inoculation with 5 x 103 blood 
trypomastigotes of pathogenic strain (Queretaro) of T. 
cruzi.  Both  groups  developed  blood  parasitemia  on 
day 10 p.i., but on day 22 p.i., MIF-/- mice displayed 
significantly  greater  levels  of  parasitemia,  which Int. J. Biol. Sci. 2011, 7 
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peaked at day 36 p.i. and could be detected until day 
50  p.i.  (Fig.  1A).  In  contrast,  the  maximum  peak  of 
parasitemia in WT mice was observed on day 27 p.i., 
and these mice controlled the infection by day 40. In-
terestingly, MIF-/- mice also began to succumb to in-
fection as early as day 23 p.i., and only 37% of them 
survived until day 45. In contrast, 65% of WT mice 
survived the infection over the time-course examined 
(Fig. 1B). 
 
 
Fig. 1. MIF is required to survive to Trypanosoma 
cruzi infection. WT and MIF
-/- mice were infected i.p. with 
3x10
3  trypomastigotes.  The  number  of  blood  trypo-
mastigotes  per  mouse  was  determined  by  counting  in  a 
Neubauer chamber (A).  The survival curve of infected MIF
-/- 
and WT mice is also shown (B). The data are expressed as 
the means with standard error (SE) and are representative 
of three independent experiments. Six animals were used in 
each group. *P< 0.002 using Student´s t test in (A) and *P< 
0.006 using a Log-rank test (B). 
 
 
Proinflammatory cytokines are impaired in 
MIF-/- mice during early T. cruzi infection 
It has been shown that the increased susceptibil-
ity  and  mortality  of  MIF-/-  mice  correlates  with  an 
altered production of IL-12, IFN-, TNF- and IL-1 
[29]. We sought to investigate how early the decreased 
production of these cytokines could be detected. We 
compared  the  MIF,  IL-12,  IFN-,  TNF-  and  IL-1 
levels in the sera of T. cruzi-infected WT and MIF-/- 
mice as early as 12 hours post-infection until 72 hours 
post-infection. After infection with T. cruzi, WT mice 
displayed rapid production of TNF-, IL-1, IL-12 and 
IFN- (Fig. 2A to E), and the levels were increased at 
72  hours  after  infection.  Importantly,  MIF  secretion 
was detectable at least 12 h after infection. In contrast, 
MIF-/- mice displayed a significant impairment in the 
production of all of the cytokines listed in the early 
infection (Fig. 3A and E).  
Dynamics of DC activation in response to T. 
cruzi infection 
To gain insight into the mechanisms involved in 
the MIF-dependent resistance to T. cruzi infection, we 
evaluated whether a lack of MIF would affect in vivo 
DC maturation during T. cruzi infection. We measured 
the kinetics of DC  maturation  marker expression in 
the  mesenteric  lymph  nodes  from  day  3  to  15  after 
infection. As shown in figure 3, there was a striking 
reduction  in  MHC-II  expression  on  DCs  at  day  3 
post-infection in MIF-/- mice relative to WT animals. 
Additionally, lower expression levels of costimulatory 
molecules, such as CD80, CD86 and OX40L, were also 
observed in MIF-/- mice, particularly on day 3 after i.p. 
infection. These findings demonstrate that the absence 
of endogenous MIF affects the expression of molecules 
related to antigen presentation in DCs. 
T. cruzi antigen-driven stimulation of MHC 
class II and costimulatory molecule expression 
by DCs is dependent on autocrine MIF 
To compare the capability of TcAg to induce the 
maturation  of  DCs  in  MIF-/-  versus  WT  mice,  we 
pulsed  bone  marrow-derived  DCs  with  TcAg  (100 
g/ml) for 24 h, and the expression of MHC-II and 
costimulatory  molecules  by  CD11c+  DC  was  evalu-
ated  by  comparing  the  expression  levels  with  those 
induced  by  the  microbe-derived  stimulator  LPS, 
which was chosen for its known ability to mature and 
activate DCs [12]. TcAg treatment induced the matu-
ration of WT DC, resulting in an upregulation of sev-
eral maturation markers (MHC-II, CD86, CD80, and 
OX40L) (Fig. 4A). Interestingly, the expression of these 
molecules was lower on MIF-/- DCs following expo-
sure to either LPS or TcAg as compared to WT DCs 
(Figure 4B). These findings demonstrate that the ab-
sence  of  endogenous  MIF  affects  the  expression  of 
molecules related to antigen presentation in DCs. Int. J. Biol. Sci. 2011, 7 
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Fig. 2. Proinflammatory cytokines are diminished in the absence of MIF. The levels of MIF (A), TNF-α (B), IL-1 
(C), IL-12 (D), and IFN-γ (E) in the sera from MIF-/- and WT mice infected with 3x10
3 blood trypomastigotes of T. cruzi. For 
the assessment of systemic cytokine production, the mice were bled at the indicated time points, and the levels of cytokines 
were determined by ELISA as described above. The values presented are the mean + SE of triplicate samples with 6 animals 
per time point per group. * P< 0.05 using Student’s t-test. 
 
Fig. 3. Surface expression of MHC-II, CD80, CD86 and OX40L on mesenteric DCs in T. cruzi-infected WT 
and MIF
-/- mice. MIF
-/- or WT mice were infected i.p. with 5 x 10
3 blood trypomastigotes. DCs from the mesenteric lymph 
nodes were harvested at 0, 3, 7, 10 and 15 days post-infection, and 1 x 10
7 cells/ml were processed by flow cytometric 
analysis. CD11c
+ cells were analyzed for the expression of MHC-II, CD80, CD86 and OX40L. Open squares correspond to 
WT DCs, and solid black squares correspond to MIF
-/- DCs. The flow cytometry profiles are representative of three ex-
periments. *P <0.05 with respect to WT using Student’s t-test. Int. J. Biol. Sci. 2011, 7 
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Fig. 4. MIF
-/- bone marrow-derived DCs fail to mature after TcAg stimulation in vitro. (A) Immature DCs were 
incubated with TcAg (50 g/ml) or LPS (1 g/ml) for 24 h, and activation was determined by measuring the expression of 
MHC-II, CD80, CD86 and OX40L. B) One of three representative histograms from bone marrow-derived DCs is shown. 
The open white histogram represents the isotype control, the closed black histogram represents the bone marrow-derived 
DCs from WT mice, and the closed gray histogram represents DCs from MIF
-/- mice. 
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T. cruzi antigen-pulsed MIF-/- DCs have im-
paired antigen-specific cytokine production 
The cytokine profile generated by APCs during 
the early interaction with pathogen-derived molecules 
is critical for the polarization of cellular responses. We 
investigated this profile in the culture supernatants of 
bone marrow DCs following a 24 h pulse with TcAg. 
WT and MIF-/- DC upregulated the secretion of the 
proinflammatory  cytokines  IL-12  and  TNF-  in  re-
sponse to TcAg stimulation, but the levels of both cy-
tokines were significantly higher in the WT DCs than 
in the MIF-/- DCs (Figure 5A and B).  
 
 
 
 
 
Fig 5. MIF is important for DC IL-12 responses to 
TcAg. Bone marrow-derived DCs from WT or MIF-/- mice 
were incubated with TcAg (50 g/ml) or LPS (1 g/ml) for 
24 h, and activation was determined by measuring the level 
of IL-12 (p40) (A) or TNF- released into supernatants by 
ELISA. The data are the average of three mice in each group. 
The black bars indicate MIF-/- mice. An asterisk indicates 
statistical significance (*P < 0.05) using Student’s t-test. 
 
We also determined the levels of the regulatory 
cytokine IL-10 and found that IL-10 production was 
impaired in MIF-/- DCs (data not shown). These re-
sults suggest that TcAg promotes a cytokine profile 
that is dominated by the presence of the proinflam-
matory  cytokines  IL-12  and  TNF-  in  WT  DCs, 
whereas  the  same  stimulus  induces  a  poor  proin-
flammatory cytokine profile characterized by a lower 
level of production of IL-12 and TNF- in MIF-/- DCs. 
T. cruzi antigen enhances ERK activation in-
dependent of MIF, but p38 phosphorylation 
depends on TcAg-MIF synergism in bone 
marrow-derived DCs  
LPS, TcAg and other TLR ligands activate MAPK 
and the subsequent cytokine production [12, 41, 42]. 
We analyzed the activation of reported key regulators 
involved in cytokine production and DC differentia-
tion  [43,  44],  such  as  extracellular  signal-regulated 
kinase (ERK)-1/2 MAPK, which has been implicated 
in blocking IL-12 in DCs through the stabilization of 
c-fos, and the p38 MAPK pathway, which has been 
implicated in IL-12 production [45, 46]. 
DCs  were  stimulated  with  phor-
bol-12-myristatc-13 acetate (PMA) as a positive control 
or  TcAg  for  30 min.  TcAg  and  PMA  increased  the 
phosphorylation  of  the  ERK1/2  MAPK  pathway  in 
WT and MIF-/- DCs to a similar level (Fig. 6A, B). As 
shown  in  Fig.  6C  and  D,  TcAg  induced  p38  phos-
phorylation on WT DC; but unlike PMA, TcAg had no 
effect on p38 phosphorylation in MIF-/- DC. Thus, the 
early recognition of TcAg induces ERK1/2 phosphor-
ylation in DCs, but synergism between MIF and TcAg 
apparently  induces  DC  activation  via  the  p38  path-
way.   
To confirm whether the activation of p38 is asso-
ciated with MIF secretion, we pulsed MIF-/- DCs with 
TcAg or PMA and restored MIF with exogenous rMIF. 
We found that TcAg or rMIF leads to a slight upregu-
lation of p38 in MIF-/- DCs, but when both rMIF and 
TcAg were added to MIF-/- DC cultures, a strong up-
regulation of p38 was observed (Fig. 6E, F). As shown 
in  Fig.  6E  and  F,  the  inhibitor  of  the  p38  pathway, 
SB203580, significantly reduced the signal activation 
during the TcAg plus rMIF treatment (P < 0.001). In 
contrast, TcAg plus rMIF without the inhibitor did not 
reduce the p38 signal activation (Fig. 6 E and F). Thus, 
our results indicate that MIF and TcAg synergize to 
induce DC activation via the p38 pathway.  
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Fig 6. TcAg enhances phospho-ERK independent of MIF, but phospho-38 is related to MIF modulation. Bone 
marrow-derived DCs from WT and MIF
-/- mice were pulsed for 30 min with TcAg or PMA as described. ERK (A) and p38 (C) 
phosphorylation was determined by flow cytometry. One representative histogram for ERK (B) and p38 (D) phosphory-
lation of three is shown. (E) MIF
-/- DCs pulsed with TcAg, rMIF, TcAg+rMIF or PMA as control with or without the p38 
inhibitor. (F) Representative histogram for MIF
-/- DCs pulsed with rMIF or TcAg+rMIF with or without the inhibitor. An 
asterisk indicates statistical significance (*p < 0.05 using Student’s t-test). 
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The p38 pathway is involved in the T. cruzi-MIF 
modulatory response  
To  determine  whether  the  activation  of  p38  is 
associated  with  costimulatory  molecule  expression, 
we pre-treated WT-DCs with the inhibitor SB203580 or 
the vehicle (as described in the materials and methods 
section) followed by incubation with TcAg or LPS for 
30  min.  Next,  we  measured  DC  maturation  marker 
expression, specifically that of MHC-II, CD86, CD80 
and  OX40L.  As  expected,  WT  DCs  stimulated  with 
TcAg or LPS displayed enhanced expression of cost-
imulatory  molecules  (Fig.  7A-D).  The  inhibition  of 
phospho- p38 only impacted MHC-II and CD86 ex-
pression during TcAg stimulation (P < 0.001), and no 
differences  in  CD80  and  OX40L  expression  were 
found. Further, the inhibitor did not affect costimula-
tory molecule expression upon LPS treatment (Figure 
7C-D). As previously demonstrated, MIF-/- DCs had 
impaired  costimulatory  molecule  expression  in  re-
sponse to both TcAg and LPS stimulation (Fig. 7A-D). 
When we added exogenous rMIF, a recovery of the 
expression of MHC-II, CD86 and CD80 was evident, 
but this recovery was not observed for OX40L. Again, 
p38 inhibition only impacted MHC-II and CD86 ex-
pression (Fig. 7 A, B). Thus, our results confirm that 
the p38 pathway is involved in a specific T. cruzi-MIF 
modulatory response in DCs. 
 
 
Fig 7. p38 phosphorylation is MIF-dependent. DCs (2 x 10
5 cells/ml) were pretreated for 2 h with the p38 inhibitor 
SB203580 (10 M) or the vehicle (DMSO), then were stimulated with TcAg (50 g/ml) or LPS (1 g/ml) for 18 h, p38 
phosphorylation was determined by flow cytometry. A) MHC-II, B) CD86, C) CD80 and D) OX40L expression is shown. 
One representative experiment of two is shown. An asterisk indicates statistical significance (*P < 0.05 using Student’s 
t-test). 
 
Discussion 
Antigen  presenting  cells,  such  as  DCs,  are  re-
sponsible for initiating the primary immune response 
and for the development of immunity and/or toler-
ance [47-49]. They are endowed with a unique capac-
ity to “sense” pathogens or pathogen-derived mole-
cules  through  receptors  with  specificity  for  patho-
gen-associated  molecular  patterns  (PAMPs)  [50].  T. 
cruzi  can  be  recognized  by  DC  through  different 
transmembrane  proteins  called  Toll-like  receptors 
(TLRs) by recognizing conserved microbial structures. 
For  example  T.  cruzi-derived  Tc52  and  glyco-
sylphosphatidylinositol (GPI) can bind TLR2 [51-53], 
glycoinositolphospholipids (GIPLs), which are a sub-
set of GPI anchors from the epimastigote state of T. 
cruzi, can bind to TLR4 [54] and CpGs bind to TLR9 to 
activate DCs [48]. Indeed, the lack of adaptor proteins Int. J. Biol. Sci. 2011, 7 
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to TLRs, such as MyD88, leads to an impairment of 
MAPK  phosphorylation  and  in  consequence,  im-
paired IL-12 and TNF- production [55]. These defi-
ciencies have an important role in mediating suscep-
tibility, meaning that MyD88-/- DCs are more suscep-
tible to parasite infection [56, 57].  
It is well documented that several T. cruzi mol-
ecules have stimulatory effects [52, 53, 58]. It has been 
also demonstrated that some of these molecules trig-
ger the phosphorylation of MAPK and IB in macro-
phages  and  DCs  [52,  55].  Recently,  it  has  been 
demonstrated that T. cruzi or uncharacterized T. cruzi 
molecules target DC maturation and/or functionality 
[59-63] and are associated with  high levels of IL-10 
production by DCs [64]. Inhibition of ERK1/2 MAPK 
down-regulated  IL-10  production  and  restored  the 
stimulatory capacity of DCs, showing the importance 
of this pathway in DC modulation [12] . 
Recently, the receptors that mediate the cellular 
responses supported by MIF were identified [65-67]. 
MIF binds to CD74, which is the cell surface form of 
the  class  II  invariant  chain  (li)  [65].  However,  de-
pending on the cellular context and the stimulation 
status, MIF triggers several signaling pathways. For 
example, in B lymphocytes, tumor cells and MO, MIF 
leads  to  the  activation  of  ERK1/2  MAPK  and 
PI3K/AKT  signaling,  resulting  in  cell  proliferation, 
enhanced survival, and gene expression of the proin-
flammatory  chemokine  CXCL8  [36,  65,  68-70].  MIF 
induces matrix metallopeptidase (MMP)-9 expression 
in murine MO mainly via the ERK1/2 MAPK path-
way [71]. MMP-2 production in rheumatoid synovial 
fibroblasts requires the activation of protein kinase C 
and the  JNK and SRC signaling pathways by MIF 
[72].  During  septic  shock,  MIF  mediates  the  phos-
phorylation  of  JNK  [73].  MIF  also  regulates  macro-
phage  chemotactic  responses  via  MAPK  and  Rho 
GTPase [31]. In lung adenocarcinoma cells, MIF pro-
motes  JNK-dependent  AP-1  transactivation  and  the 
subsequent transcriptional regulation of CXCL8 [74].  
MIF also has inhibitory properties. For example, 
the release of MIF inhibits signaling through JNK in 
ischemic cardiomocytes, triggering the phosphoryla-
tion of the pro-apoptotic protein BAD with an ensuing 
increase in cell death [75]. When the MIF target cells 
are pre-stimulated by stress, MIF inhibits or attenu-
ates the JNK MAPK pathway. The activation of the 
JNK pathway in fibroblasts stimulated by TNF or UV 
irradiation-induced stress  is blocked by higher con-
centrations of MIF [76].  
Direct evidence for role the of MIF in the activa-
tion on DCs came from a study on the role of MIF in 
Toxoplasma  gondii  infection  in  which  MIF-deficient 
DCs  had  impaired  IL-12  and  TNF-  production  in 
response to T. gondii antigen [22]. Here, we show that 
DCs from an in vivo T. cruzi infection or pulsed in vitro 
with TcAg  had impaired IL-12 production costimu-
latory molecule expression. These data demonstrate 
that the action of MIF is the result of its direct impact 
on DCs and that the production of IL-12 favors the 
anti-parasite  effector  mechanism  during  T. cruzi  in-
fection.  
To elucidate the intracellular events involved in 
the MIF synergism with T. cruzi antigens in DCs, we 
examined  ERK1/2  and  p38  phosphorylation.  We 
found that ERK1/2 phosphorylation was enhanced to 
a similar degree in both WT and MIF-/- DCs pulsed 
with  TcAg.  This  upregulation  of  ERK1/2  has  been 
associated with the overproduction of IL-10 by DCs 
exposed to live parasites combined with LPS, which 
synergize  to  induce  a  regulatory  phenotype  that  is 
associated with impaired costimulatory molecule ex-
pression  by  DCs  [12].  Here,  we  observed  a  similar 
level  of  ERK1/2  phosphorylation  in  both  WT  and 
MIF-/-  DCs  stimulated  with  TcAg,  indicating  that 
ERK1/2 activation is not dependent on MIF. Moreo-
ver,  we  found  high  levels  of  IL-12  secretion  and 
MHC-II and CD86 upregulation after TcAg exposure 
in  WT,  but  not  MIF-/-  DCs,  despite  the  high  phos-
phorylation of ERK1/2 in MIF-/- DCs, confirming that 
the ERK1/2 pathway is not involved in the impaired 
DC maturation and perhaps is implicated in the reg-
ulatory DC phenotype as was demonstrated by Pocini 
et al. [64]. 
The  fact  that  despite  the  phosphorylation  of 
ERK1/2,  we  detected  high  expression  of  IL-12, 
MHC-II and CD86 in WT DCs may be explained by 
the  use  of  total  antigen  (TcAg);  some  of  molecules 
inside the parasite can be released and activate TLRs, 
such as TLR2, TLR4 or TLR9 in DCs, and favor the 
balance toward inflammatory MAPK mediators, such 
as p38. This conjecture is supported by the observa-
tion that macrophages exposed to GPI from T. cruzi 
induces  p38  phosphorylation,  but  live  T.  cruzi,  in 
which these molecules could be hidden from immune 
recognition, does not [12, 55].   
Consistent  with  this  hypothesis,  we  found  en-
hanced p38 phosphorylation in WT DCs, but not in 
MIF-/-  DCs,  which  correlates  with  the  lack  of  IL-12 
production and the impaired maturation observed for 
MIF-/- DCs. This supports the hypothesis that the in-
tracellular events mediated by MIF that favor the ef-
fective  maturation  and  IL-12  production  in  DCs 
pulsed  with  TcAg  are  carried  out  through  the  p38 
signaling pathway.  
This  hypothesis  was  tested  using  exogenous 
MIF.  We  found  that  rMIF  slightly  upregulated  p38 
phosphorylation in MIF-/- DCs. Similarly, TcAg only Int. J. Biol. Sci. 2011, 7 
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slightly  increased  p38  phosphorylation.  However, 
using  TcAg  and  rMIF  together  as  stimuli,  p38  was 
highly  phosphorylated,  indicating  a  synergism  be-
tween TcAg and MIF leading to efficient DC matura-
tion.  Moreover,  the  addition  of  rMIF  to  MIF-/-  DCs 
restored IL-12 and TNF- production as well as the 
expression of maturation molecules after LPS or TcAg 
treatment. Due to the lack of p38 phosphorylation and 
the fact that rMIF restored DC maturation in MIF-/- 
DCs in response to TcAg, we hypothesized that the 
impaired  maturation  occurs  through  the  p38  path-
way. 
Finally, we demonstrated that the restored cyto-
kine production and costimulatory molecule expres-
sion were p38 dependent. Using a selective p38 in-
hibitor, we found that only IL-12, MHC-II and CD86 
were downregulated. All these findings demonstrate 
a key role for MIF in the modulation of p38 pathway 
and suggest that this regulatory effect involves para-
site-DC interactions. Thus, MAPKs appear to be in-
fluenced by MIF, wherein MIF favors the balance to-
ward inflammatory cytokine production through p38 
phosphorylation, in response to this protozoon. 
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